Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology
Latest Information Update: 01 Nov 2024
At a glance
- Drugs Verdiperstat (Primary)
- Indications Primary progressive aphasia
- Focus Adverse reactions
- Acronyms Veri-T-001
Most Recent Events
- 18 Oct 2022 Planned End Date changed from 31 Dec 2027 to 30 Sep 2026.
- 18 Oct 2022 Planned primary completion date changed from 31 Dec 2026 to 30 Jun 2026.
- 04 Aug 2022 Trial design of Veri-T trial presented at the Alzheimer's Association International Conference 2022.